TISSIUM
TISSIUM is a Paris-based medtech company developing proprietary light-activated biomorphic programmable polymers for tissue reconstruction, commercializing the FDA-authorized COAPTIUM CONNECT sutureless nerve repair system to hospitals and surgical centers while building a pipeline across hernia and cardiovascular indications.
- Company typePrivate
- Founded2013
- HeadquartersParis, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What TISSIUM does
TISSIUM (formerly Gecko Biomedical) is a Paris-headquartered, privately-held medtech company founded in 2013 that develops proprietary biomorphic programmable polymers for tissue reconstruction. The company's core technology is a family of fully biosynthetic, light-activated polymers that conform to and integrate with surrounding tissue and whose building blocks can be tuned to match tissue-specific mechanical and biological requirements; these polymers are deployed alongside 3D-printed bioresorbable chambers using proprietary digital light projection manufacturing techniques. The IP base derives from research at MIT and Brigham and Women's Hospital, and is protected by 26 patent families encompassing 88 granted patents.
TISSIUM monetizes its platform through the sale of medical devices to hospitals and surgical centers, with its first commercial product, COAPTIUM CONNECT — a sutureless peripheral nerve repair system — receiving FDA De Novo authorization in June 2025 and entering U.S. direct sales in July 2025. The company pursues an enterprise field-sales motion targeting surgical specialties, and is investing in additional pipeline indications including atraumatic hernia mesh fixation (first patients treated September 2023) and a CE-Marked vascular sealant (SETALIUM). TISSIUM operates a manufacturing facility in Roncq, France, a U.S. commercial office in Cambridge, Massachusetts, and is led by co-founder-CEO Christophe Bancel alongside co-founder Maria Pereira (Deputy CEO and CIO), with scientific co-founders Robert Langer (MIT) and Jeffrey M. Karp (Brigham and Women's Hospital) anchoring the research and clinical agenda.
The business has been funded through approximately €170 million of cumulative equity, debt, and non-dilutive capital from investors including Sofinnova Partners, Cathay Health, Omnes Capital, Bpifrance, the European Investment Bank, and others, including a €60 million package in 2025-2026 (a €30M Series D2 round plus a €30M EIB facility) earmarked for U.S. commercial launch and pipeline advancement. Revenue figures are not publicly disclosed, and the company is effectively at the very start of its commercial ramp following U.S. market entry.
TISSIUM firmographics
Firmographics- Name
- TISSIUM
- Legal name
- Tissium SA
- Website
- https://tissium.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- TISSIUM is a Paris-based medtech company developing proprietary light-activated biomorphic programmable polymers for tissue reconstruction, commercializing the FDA-authorized COAPTIUM CONNECT sutureless nerve repair system to hospitals and surgical centers while building a pipeline across hernia and cardiovascular indications.
- Ownership category
- akta.pro rank
TISSIUM industry classification
Industry- Product category
- Surgical Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)
Keywords
Where TISSIUM is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
TISSIUM business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Medical Device Sales: Sale of medical devices for tissue reconstruction including COAPTIUM CONNECT nerve repair products and pipeline products for hernia repair and cardiovascular sealing.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
TISSIUM product offering
Product offeringCore offering
TISSIUM develops and manufactures proprietary biomorphic programmable polymers used as surgical sealants and adhesives for tissue reconstruction in open and minimally invasive procedures. Its lead commercial product, COAPTIUM® CONNECT, is an FDA-authorized sutureless peripheral nerve repair system that combines a light-activated polymer with a bioresorbable 3D-printed biopolymer chamber to coapt severed nerve endings without sutures. The polymer platform is also being applied to pipeline products for atraumatic hernia mesh fixation and vascular sealing.
Product overview
TISSIUM offers a biopolymer platform with multiple product lines. The core platform consists of proprietary biomorphic programmable polymers that conform to and integrate with surrounding tissue. The flagship commercial product is COAPTIUM® CONNECT, the first FDA-authorized sutureless nerve repair system. The product portfolio includes COAPTIUM® Nerve Products for peripheral nerve repair, hernia repair products using atraumatic fixation technology, and cardiovascular sealant products including SETALIUM™ Vascular Sealant. The platform supports multiple therapeutic areas (peripheral nerve, cardiovascular, gastrointestinal) with delivery and activation devices for enhanced performance.
Differentiator
Problem solved
Functional benefit
Brands
- COAPTIUM CONNECT: FDA-authorized sutureless peripheral nerve repair system using biomorphic programmable polymers
- COAPTIUM Nerve Products
- SETALIUM Vascular Sealant
Products and services
- COAPTIUM® CONNECT First and only FDA-authorized system for atraumatic sutureless nerve coaptation, using a light-activated surgical polymer within a bioresorbable 3D-printed biopolymer chamber to join severed peripheral nerve endings without sutures. Commercially available in the United States and intended for hospitals and surgical centers performing peripheral nerve repair.
- COAPTIUM® Nerve Products Product line for peripheral nerve repair, including the COAPTIUM® CONNECT sutureless nerve coaptation system and 3D-printed biopolymer nerve chambers used in atraumatic nerve repair procedures. Targeted at hand, peripheral nerve, plastic, and trauma surgeons in hospitals and surgical centers.
- SETALIUM™ Vascular Sealant Sterile, biodegradable, bioresorbable sealant in a pre-filled syringe for vascular reconstruction and hemostasis during peripheral vascular surgery. CE Marked for the European market and under FDA IDE in the United States; intended as a complement to sutures for effective surgical closure and prevention of post-operative bleeding.
Quantifiable outcome
- Enhanced reinnervation and increased muscle weight in animal studies with sutureless nerve repair system
- +1 more outcomes
Companies that use TISSIUM
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
TISSIUM technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
TISSIUM partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- NYU LangoneminorClinical collaboration with surgeons from NYU Langone for research on sutureless nerve repair system.
- Brigham & Women's HospitalcoreCo-founder Robert Langer and Jeffrey Karp from Brigham & Women's Hospital; ongoing clinical collaboration on nerve repair research.
- SUNY Downstate Medical CenterminorCollaboration with surgeons from SUNY Downstate for research on sutureless nerve repair.
- TÜV SÜDcoreDesignated notified body under European MDR that provided ISO 13485:2016 compliance certification and CE mark for vascular sealant products.
Scale indicators10 records
Recent moves8 records
Expansion highlights6 records
TISSIUM competitors and assessment
Company assessmentDirect peers
- Baxter International: Baxter's BioSurgery division offers TISSEEL fibrin sealant and FLOSEAL hemostatic matrix, the most directly comparable surgical sealant franchise to TISSIUM's SETALIUM and COAPTIUM lines. Baxter competes in the same surgical closure and tissue reconstruction categories across similar hospital customers.
- Artivion: Artivion (formerly CryoLife) markets BioGlue, a surgical adhesive used in cardiovascular and reconstructive surgery. Artivion is a focused direct competitor in synthetic surgical adhesives for vascular and tissue reconstruction, overlapping with TISSIUM's SETALIUM vascular sealant.
- Advanced Medical Solutions: Advanced Medical Solutions is a UK-based specialty medtech focused on tissue adhesives (LiquiBand) and collagen-based sealants (RESORBA). AMS is a directly comparable mid-sized peer in the surgical sealants and adhesives market with overlapping indications in wound closure.
- Integra LifeSciences: Integra LifeSciences offers DuraGen and other surgical sealant products for neurosurgery and tissue reconstruction. Integra competes in adjacent specialty surgical closure markets and is similar in scale to TISSIUM with a comparable specialty surgical focus.
Broad incumbents
- Johnson & Johnson (Ethicon): Ethicon offers EVICEL fibrin sealant and SURGIFLO hemostatic matrix as part of a broad surgical portfolio. While much larger than TISSIUM, Ethicon competes directly in the surgical sealant/adhesive category and serves the same hospital and surgical center customers.
- Medtronic: Medtronic's Surgical Innovations division offers hemostatic and sealant products as part of a broad surgical portfolio. While Medtronic's surgical sealants are not its primary focus, it competes for the same hospital purchasing relationships and surgical closure budgets.
- Becton Dickinson (BD): BD offers surgical hemostasis products including the Avitene family of collagen-based hemostats and other adjunctive hemostatic agents. BD competes in surgical tissue sealing through its broad medical device portfolio targeting the same hospital and surgical center customers.
- Stryker: Stryker acquired Cohera Medical (maker of Sylys surgical sealant) and operates a broad surgical equipment portfolio. Stryker competes broadly in surgical devices and now directly in surgical sealants through Cohera's assets.
- Smith+Nephew: Smith+Nephew offers advanced wound management and surgical products including tissue adhesives for wound closure. While broader than TISSIUM, Smith+Nephew serves overlapping surgical and wound care end markets with established commercial infrastructure.
Emerging players
- Arch Therapeutics: Arch Therapeutics develops AC5, a self-assembling peptide hemostatic agent for surgical and wound care applications. Arch is an emerging, smaller competitor focused on a specific niche within surgical sealants and hemostats, partially overlapping with TISSIUM's platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TISSIUM social profiles
Digital presenceTISSIUM compliance and trust
Trust signalCompliance4 records
TISSIUM financial estimates
Financial estimateRevenue estimate
Valuation estimate
TISSIUM leadership team
Management profileNumber of profiles
Profiles16 records
TISSIUM funding detail
Funding detailFunding overview
Funding rounds12 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TISSIUM M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TISSIUM
What does TISSIUM do?
TISSIUM develops and manufactures proprietary biomorphic programmable polymers used as surgical sealants and adhesives for tissue reconstruction in open and minimally invasive procedures. Its lead commercial product, COAPTIUM® CONNECT, is an FDA-authorized sutureless peripheral nerve repair system that combines a light-activated polymer with a bioresorbable 3D-printed biopolymer chamber to coapt severed nerve endings without sutures. The polymer platform is also being applied to pipeline products for atraumatic hernia mesh fixation and vascular sealing.
Is TISSIUM a public or private company?
TISSIUM is a private company. It is classified as venture growth investor backed and is currently operating.
When was TISSIUM founded?
TISSIUM was founded in 2013. It employs 101 to 250 people.
Where is TISSIUM based?
TISSIUM is headquartered in Paris, France, in the Europe region.
How does TISSIUM make money?
One revenue line is on record: medical Device Sales.
Who are TISSIUM's main competitors?
Direct peers on record are Baxter International, Artivion, Advanced Medical Solutions and Integra LifeSciences. Broad incumbents are Johnson & Johnson (Ethicon), Medtronic, Becton Dickinson (BD), Stryker and Smith+Nephew. Arch Therapeutics is listed as an emerging player.
Does TISSIUM have an API?
No public API is recorded for TISSIUM.
What industry is TISSIUM in?
TISSIUM's product category is Surgical Medical Devices. Its primary akta.pro industry code is HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 339113 and its SIC code is 3841.